Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy
Childhood onset chronic inflammatory demyelinating polyneuropathy (CIDP) often requires long‐term immunomodulatory therapy. We report a comprehensive review of our treatment of pediatric CIDP with a focus on high‐dose weekly corticosteroids (“pulse oral corticosteroids”), a treatment method that is...
Gespeichert in:
| Veröffentlicht in: | Muscle & nerve 2020-12, Vol.62 (6), p.705-709 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 709 |
|---|---|
| container_issue | 6 |
| container_start_page | 705 |
| container_title | Muscle & nerve |
| container_volume | 62 |
| creator | Rogers, Amanda B. Zaidman, Craig M. Connolly, Anne M. |
| description | Childhood onset chronic inflammatory demyelinating polyneuropathy (CIDP) often requires long‐term immunomodulatory therapy. We report a comprehensive review of our treatment of pediatric CIDP with a focus on high‐dose weekly corticosteroids (“pulse oral corticosteroids”), a treatment method that is not commonly reported. We retrospectively reviewed medical records of pediatric patients with CIDP treated at our center between 2000 and 2018 for whom we had at least 12 mo follow‐up. Here, we describe the demographics, disease course, treatment regimens, and long‐term outcomes of these patients. Twenty‐five patients were identified for analysis. Pulse oral corticosteroid monotherapy was the predominant maintenance treatment in 56% of patients. Patients were followed for a median of 4 y. Side effects were seen in a minority of patients. The probability of a normal exam or being off treatment at last follow‐up was similar regardless of predominant maintenance therapy. Pulse oral corticosteroid therapy is a safe and effective long‐term treatment option in children with CIDP. |
| doi_str_mv | 10.1002/mus.27058 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2462027549</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2462027549</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3538-2c0cf9f6a346aab1d95b2dc594f7173087fad9469136d3825d28abf08b9f545b3</originalsourceid><addsrcrecordid>eNp1kMtKw0AARQdRbK0u_AEJuHKRdp7JzFKKL6goaEFXYTIPOyXJxJkEyd8brbpzdTeHc-EAcIrgHEGIF3Uf5ziHjO-BKYIiTykTfB9MIaI8zYh4mYCjGLcQQsSz_BBMCOaCEMqn4PWxr6JJfJBVonzonPKxM8E7HRPXJK3RTnbBqURtgm_GdY2tZF3Lzoch0aYeTOUa2bnmLWl9NTSmD76V3WY4BgdWju6Tn52B9fXV8_I2XT3c3C0vV6kijPAUK6issJkkNJOyRFqwEmvFBLU5ygnkuZVa0EwgkmnCMdOYy9JCXgrLKCvJDJzvvG3w772JXbH1fWjGywLTDEOcMypG6mJHqeBjDMYWbXC1DEOBYPEVsRgjFt8RR_bsx9iXtdF_5G-1EVjsgA9XmeF_U3G_ftopPwGGB32u</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2462027549</pqid></control><display><type>article</type><title>Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Rogers, Amanda B. ; Zaidman, Craig M. ; Connolly, Anne M.</creator><creatorcontrib>Rogers, Amanda B. ; Zaidman, Craig M. ; Connolly, Anne M.</creatorcontrib><description>Childhood onset chronic inflammatory demyelinating polyneuropathy (CIDP) often requires long‐term immunomodulatory therapy. We report a comprehensive review of our treatment of pediatric CIDP with a focus on high‐dose weekly corticosteroids (“pulse oral corticosteroids”), a treatment method that is not commonly reported. We retrospectively reviewed medical records of pediatric patients with CIDP treated at our center between 2000 and 2018 for whom we had at least 12 mo follow‐up. Here, we describe the demographics, disease course, treatment regimens, and long‐term outcomes of these patients. Twenty‐five patients were identified for analysis. Pulse oral corticosteroid monotherapy was the predominant maintenance treatment in 56% of patients. Patients were followed for a median of 4 y. Side effects were seen in a minority of patients. The probability of a normal exam or being off treatment at last follow‐up was similar regardless of predominant maintenance therapy. Pulse oral corticosteroid therapy is a safe and effective long‐term treatment option in children with CIDP.</description><identifier>ISSN: 0148-639X</identifier><identifier>EISSN: 1097-4598</identifier><identifier>DOI: 10.1002/mus.27058</identifier><identifier>PMID: 32893348</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Administration, Oral ; Adolescent ; Adrenal Cortex Hormones - administration & dosage ; Child ; Child, Preschool ; Children ; CIDP ; Corticoids ; Corticosteroids ; Demography ; Demyelination ; Duration of Therapy ; Female ; Glucocorticoids - administration & dosage ; Health services ; Humans ; Immunoglobulins, Intravenous - therapeutic use ; Immunologic Factors - therapeutic use ; Immunomodulation ; immunomodulatory therapy ; Infant ; Inflammation ; inflammatory neuropathy ; Irritable Mood ; Maintenance ; Maintenance Chemotherapy ; Male ; Medical records ; Medical treatment ; Patients ; pediatric CIDP ; Pediatrics ; Polyneuropathy ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology ; Prednisone - administration & dosage ; Pulse Therapy, Drug ; Side effects ; Sleep Initiation and Maintenance Disorders - chemically induced ; Therapy ; Weight Gain ; Young Adult</subject><ispartof>Muscle & nerve, 2020-12, Vol.62 (6), p.705-709</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020 Wiley Periodicals LLC.</rights><rights>2020 Wiley Periodicals, LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3538-2c0cf9f6a346aab1d95b2dc594f7173087fad9469136d3825d28abf08b9f545b3</citedby><cites>FETCH-LOGICAL-c3538-2c0cf9f6a346aab1d95b2dc594f7173087fad9469136d3825d28abf08b9f545b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmus.27058$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmus.27058$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32893348$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rogers, Amanda B.</creatorcontrib><creatorcontrib>Zaidman, Craig M.</creatorcontrib><creatorcontrib>Connolly, Anne M.</creatorcontrib><title>Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy</title><title>Muscle & nerve</title><addtitle>Muscle Nerve</addtitle><description>Childhood onset chronic inflammatory demyelinating polyneuropathy (CIDP) often requires long‐term immunomodulatory therapy. We report a comprehensive review of our treatment of pediatric CIDP with a focus on high‐dose weekly corticosteroids (“pulse oral corticosteroids”), a treatment method that is not commonly reported. We retrospectively reviewed medical records of pediatric patients with CIDP treated at our center between 2000 and 2018 for whom we had at least 12 mo follow‐up. Here, we describe the demographics, disease course, treatment regimens, and long‐term outcomes of these patients. Twenty‐five patients were identified for analysis. Pulse oral corticosteroid monotherapy was the predominant maintenance treatment in 56% of patients. Patients were followed for a median of 4 y. Side effects were seen in a minority of patients. The probability of a normal exam or being off treatment at last follow‐up was similar regardless of predominant maintenance therapy. Pulse oral corticosteroid therapy is a safe and effective long‐term treatment option in children with CIDP.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adrenal Cortex Hormones - administration & dosage</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>CIDP</subject><subject>Corticoids</subject><subject>Corticosteroids</subject><subject>Demography</subject><subject>Demyelination</subject><subject>Duration of Therapy</subject><subject>Female</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Health services</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunomodulation</subject><subject>immunomodulatory therapy</subject><subject>Infant</subject><subject>Inflammation</subject><subject>inflammatory neuropathy</subject><subject>Irritable Mood</subject><subject>Maintenance</subject><subject>Maintenance Chemotherapy</subject><subject>Male</subject><subject>Medical records</subject><subject>Medical treatment</subject><subject>Patients</subject><subject>pediatric CIDP</subject><subject>Pediatrics</subject><subject>Polyneuropathy</subject><subject>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy</subject><subject>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology</subject><subject>Prednisone - administration & dosage</subject><subject>Pulse Therapy, Drug</subject><subject>Side effects</subject><subject>Sleep Initiation and Maintenance Disorders - chemically induced</subject><subject>Therapy</subject><subject>Weight Gain</subject><subject>Young Adult</subject><issn>0148-639X</issn><issn>1097-4598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtKw0AARQdRbK0u_AEJuHKRdp7JzFKKL6goaEFXYTIPOyXJxJkEyd8brbpzdTeHc-EAcIrgHEGIF3Uf5ziHjO-BKYIiTykTfB9MIaI8zYh4mYCjGLcQQsSz_BBMCOaCEMqn4PWxr6JJfJBVonzonPKxM8E7HRPXJK3RTnbBqURtgm_GdY2tZF3Lzoch0aYeTOUa2bnmLWl9NTSmD76V3WY4BgdWju6Tn52B9fXV8_I2XT3c3C0vV6kijPAUK6issJkkNJOyRFqwEmvFBLU5ygnkuZVa0EwgkmnCMdOYy9JCXgrLKCvJDJzvvG3w772JXbH1fWjGywLTDEOcMypG6mJHqeBjDMYWbXC1DEOBYPEVsRgjFt8RR_bsx9iXtdF_5G-1EVjsgA9XmeF_U3G_ftopPwGGB32u</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Rogers, Amanda B.</creator><creator>Zaidman, Craig M.</creator><creator>Connolly, Anne M.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>202012</creationdate><title>Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy</title><author>Rogers, Amanda B. ; Zaidman, Craig M. ; Connolly, Anne M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3538-2c0cf9f6a346aab1d95b2dc594f7173087fad9469136d3825d28abf08b9f545b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adrenal Cortex Hormones - administration & dosage</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>CIDP</topic><topic>Corticoids</topic><topic>Corticosteroids</topic><topic>Demography</topic><topic>Demyelination</topic><topic>Duration of Therapy</topic><topic>Female</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Health services</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunomodulation</topic><topic>immunomodulatory therapy</topic><topic>Infant</topic><topic>Inflammation</topic><topic>inflammatory neuropathy</topic><topic>Irritable Mood</topic><topic>Maintenance</topic><topic>Maintenance Chemotherapy</topic><topic>Male</topic><topic>Medical records</topic><topic>Medical treatment</topic><topic>Patients</topic><topic>pediatric CIDP</topic><topic>Pediatrics</topic><topic>Polyneuropathy</topic><topic>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy</topic><topic>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology</topic><topic>Prednisone - administration & dosage</topic><topic>Pulse Therapy, Drug</topic><topic>Side effects</topic><topic>Sleep Initiation and Maintenance Disorders - chemically induced</topic><topic>Therapy</topic><topic>Weight Gain</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rogers, Amanda B.</creatorcontrib><creatorcontrib>Zaidman, Craig M.</creatorcontrib><creatorcontrib>Connolly, Anne M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Muscle & nerve</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rogers, Amanda B.</au><au>Zaidman, Craig M.</au><au>Connolly, Anne M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy</atitle><jtitle>Muscle & nerve</jtitle><addtitle>Muscle Nerve</addtitle><date>2020-12</date><risdate>2020</risdate><volume>62</volume><issue>6</issue><spage>705</spage><epage>709</epage><pages>705-709</pages><issn>0148-639X</issn><eissn>1097-4598</eissn><abstract>Childhood onset chronic inflammatory demyelinating polyneuropathy (CIDP) often requires long‐term immunomodulatory therapy. We report a comprehensive review of our treatment of pediatric CIDP with a focus on high‐dose weekly corticosteroids (“pulse oral corticosteroids”), a treatment method that is not commonly reported. We retrospectively reviewed medical records of pediatric patients with CIDP treated at our center between 2000 and 2018 for whom we had at least 12 mo follow‐up. Here, we describe the demographics, disease course, treatment regimens, and long‐term outcomes of these patients. Twenty‐five patients were identified for analysis. Pulse oral corticosteroid monotherapy was the predominant maintenance treatment in 56% of patients. Patients were followed for a median of 4 y. Side effects were seen in a minority of patients. The probability of a normal exam or being off treatment at last follow‐up was similar regardless of predominant maintenance therapy. Pulse oral corticosteroid therapy is a safe and effective long‐term treatment option in children with CIDP.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>32893348</pmid><doi>10.1002/mus.27058</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0148-639X |
| ispartof | Muscle & nerve, 2020-12, Vol.62 (6), p.705-709 |
| issn | 0148-639X 1097-4598 |
| language | eng |
| recordid | cdi_proquest_journals_2462027549 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Administration, Oral Adolescent Adrenal Cortex Hormones - administration & dosage Child Child, Preschool Children CIDP Corticoids Corticosteroids Demography Demyelination Duration of Therapy Female Glucocorticoids - administration & dosage Health services Humans Immunoglobulins, Intravenous - therapeutic use Immunologic Factors - therapeutic use Immunomodulation immunomodulatory therapy Infant Inflammation inflammatory neuropathy Irritable Mood Maintenance Maintenance Chemotherapy Male Medical records Medical treatment Patients pediatric CIDP Pediatrics Polyneuropathy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology Prednisone - administration & dosage Pulse Therapy, Drug Side effects Sleep Initiation and Maintenance Disorders - chemically induced Therapy Weight Gain Young Adult |
| title | Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T17%3A28%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pulse%20oral%20corticosteroids%20in%20pediatric%20chronic%20inflammatory%20demyelinating%20polyneuropathy&rft.jtitle=Muscle%20&%20nerve&rft.au=Rogers,%20Amanda%20B.&rft.date=2020-12&rft.volume=62&rft.issue=6&rft.spage=705&rft.epage=709&rft.pages=705-709&rft.issn=0148-639X&rft.eissn=1097-4598&rft_id=info:doi/10.1002/mus.27058&rft_dat=%3Cproquest_cross%3E2462027549%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2462027549&rft_id=info:pmid/32893348&rfr_iscdi=true |